Dyadic International Upgraded By OTC Markets To "Current Information" Tier Highest trading tier on the OTC Pink marketplace
JUPITER, Fla., Jan. 23, 2013 /PRNewswire/ -- Dyadic International, Inc., a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries, announced today that it has been upgraded by OTC Markets to "Current Information" which is the highest trading tier on the OTC Pink marketplace. The disclosures required for this upgrade have been posted on the OTC Markets website (www.otcmarkets.com) under Dyadic's ticker symbol, "DYAI."
Dyadic's President and CEO, Mark Emalfarb, stated, "Completion of the upgrade to OTC Pink Current Information is one of several positive steps Dyadic has taken to strengthen our stockholder base and build stockholder value by providing greater transparency through periodic press releases and quarterly and annual disclosures, financial statements and investor conference calls. The confidence and protections provided by these additional disclosures contribute to the significantly greater liquidity of the OTC Pink Current Information Tier as compared to the prior tier assigned to Dyadic."
The Current Information Tier applies to reporting companies that submit filings to regulators with powers of review and that make the filings publicly available and non-reporting companies that make current information publicly available on the OTC Disclosure and News Service pursuant to OTC Markets Guidelines for Providing Adequate Current Information. Disclosures are published pursuant to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of Rule 240.15c2-11 and the OTC Disclosure Guidelines.
Dyadic International, Inc. is a global biotechnology company that uses its patented and proprietary technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzyme industries.
Dyadic utilizes an integrated technology platform based on its patented and proprietary C1 fungus, which enables the development and large scale manufacture of low cost enzymes and other proteins for diverse market opportunities. The C1 platform technology can also be used to screen for the discovery of novel genes and proteins. Dyadic actively pursues licensing arrangements and other commercial opportunities to leverage the value of these technologies by providing its partners and collaborators with the benefits of manufacturing and/or utilizing the enzymes which these technologies help produce. Please visit Dyadic's website at www.dyadic.com.
Cautionary Statement for Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause Dyadic's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, Dyadic expressly disclaims any intent or obligation to update any forward-looking statements.
SOURCE Dyadic International, Inc.